AI drug development

AlphaProteo is the first AI system launched by DeepMind to design new, high-strength protein conjugates as building blocks for biological and health research. This technology has the potential to accelerate our understanding of biological processes and facilitate the discovery of new drugs, the development of biosensors, and more. AlphaProteo generates novel protein conjugates for a variety of target proteins, including VEGF-A, which is associated with cancer and diabetes complications. It outperforms existing methods in terms of experimental success rate and binding affinity, and can significantly reduce the time required for preliminary experiments involving protein conjugates.